Literature DB >> 27810399

Associations between hemoglobin concentrations and the development of incidental metabolic syndrome or nonalcoholic fatty liver disease.

Goh Eun Chung1, Jeong Yoon Yim2, Donghee Kim3, Min-Sun Kwak1, Jong In Yang1, Su Jin Chung1, Sun Young Yang1, Joo Sung Kim4.   

Abstract

AIMS: Hemoglobin (Hb) is known to be associated with both nonalcoholic fatty liver disease (NAFLD) and metabolic syndrome (MS). We evaluated the relationship between serum Hb levels and the development of MS or NAFLD.
METHODS: A retrospective cohort study was conducted. We recruited participants who underwent abdominal ultrasonography and blood samplings in both 2005 and 2010.
RESULTS: Graded independent relationships were observed between higher Hb levels and the incidence of MS and NAFLD. After adjusting for age, body mass index, and fasting glucose, high-density lipoprotein cholesterol and triglyceride levels, the risk of developing MS was significantly higher according to the Hb quartiles in men (P for trend=0.027). The adjusted odds ratio (OR) and 95% confidence intervals (CIs) for the highest Hb quartile was 1.81 (1.06-3.10) for women and 1.43 (1.00-2.05) for men. The risk of developing NAFLD was also significantly higher according to the Hb quartiles in men (P for trend=0.03). The adjusted OR and 95% CI for the highest Hb quartile was 1.18 (0.73-1.91) in women and 1.76 (1.16-2.66) in men.
CONCLUSIONS: The risk of developing either MS or NAFLD was significantly associated with serum Hb levels in men. These findings have implications in the clinical availability of serum Hb as a predictor of MS and NAFLD.
Copyright © 2016 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Hematocrit; Hepatic steatosis

Mesh:

Substances:

Year:  2016        PMID: 27810399     DOI: 10.1016/j.dld.2016.10.004

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  7 in total

1.  The predictive value of routine laboratory tests for colorectal polyps: a retrospective study.

Authors:  Xinyi Feng; Xiuping Jiao; Yemin Xu; Xi Xu; Yan Zhu; Qiang She; Yaoyao Li; Guiqing Li; Jian Wu; Weiming Xiao; Yanbing Ding; Bin Deng
Journal:  J Gastrointest Oncol       Date:  2022-02

2.  A simple clinical model predicts incident hepatic steatosis in a community-based cohort: The Framingham Heart Study.

Authors:  Michelle T Long; Alison Pedley; Joseph M Massaro; Udo Hoffmann; Jiantao Ma; Rohit Loomba; Raymond T Chung; Emelia J Benjamin
Journal:  Liver Int       Date:  2018-03-12       Impact factor: 5.828

3.  A predictive model for the diagnosis of non-alcoholic fatty liver disease based on an integrated machine learning method.

Authors:  Xuefeng Ma; Chao Yang; Kun Liang; Baokai Sun; Wenwen Jin; Lizhen Chen; Mengzhen Dong; Shousheng Liu; Yongning Xin; Likun Zhuang
Journal:  Am J Transl Res       Date:  2021-11-15       Impact factor: 4.060

4.  Hemoglobin concentration is associated with the incidence of metabolic syndrome.

Authors:  Sunyue He; Hongxia Gu; Jie Yang; Qing Su; Xiaoyong Li; Li Qin
Journal:  BMC Endocr Disord       Date:  2021-03-19       Impact factor: 2.763

5.  Association between Hemoglobin Levels and Colorectal Polyps in Asymptomatic Chinese Adults.

Authors:  Chao Shen; Xiaoying Shi; Maram Al-Ashoor; Chengfu Xu
Journal:  Gastroenterol Res Pract       Date:  2020-01-18       Impact factor: 2.260

6.  Noninvasive indices for predicting nonalcoholic fatty liver disease in patients with chronic kidney disease.

Authors:  A Reum Choe; Dong-Ryeol Ryu; Hwi Young Kim; Hye Ah Lee; Jiyoung Lim; Jin Sil Kim; Jeong Kyong Lee; Tae Hun Kim; Kwon Yoo
Journal:  BMC Nephrol       Date:  2020-02-17       Impact factor: 2.388

7.  Red Blood Cell Count: An Unrecognized Risk Factor for Nonalcoholic Fatty Liver Disease.

Authors:  Fang Zhong; Liying Guan; Haiyan Lin; Meng Zhao; Yiming Qin; Qihang Li; Zhongshang Yuan; Guang Yang; Ling Gao; Jiajun Zhao
Journal:  Front Endocrinol (Lausanne)       Date:  2021-12-07       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.